Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203216 · ClinicalTrials.gov registry record · NA
A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches
A NA study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT00203216 is a NA study that has completed, run by Thomas Jefferson University. The registered enrollment target is 31 participants.
The verdict
NCT00203216, a NA study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
The study drug levetiracetam is FDA approved as an add-on medication in the treatment of partial onset seizures in adults with epilepsy. The trade name is Keppra®. This is an "open-label" trial, which means that all participating patients will receive active study drug. The Jefferson Headache Center has developed this clinical study to evaluate the safety and effectiveness of levetiracetam in preventing migraine headaches, with or without aura (visual disturbances). In addition, the study site will be performing a procedure called Transcranial Magnetic Stimulation (TMS). This procedure measures brain activity because it is thought that people with migraine experience periods of cortical hyperexcitability or over-activity in the brain. This information may help physicians in the future determine which preventive medications will work for which patients.
Interventions
- DRUG levetiracetam
- PROCEDURE Transcranial Magnetic Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2002-09 |
| Est. Completion | 2005-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203216
The ClinicalTrials.gov registry entry for NCT00203216 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which levetiracetam is the first listed.
NCT00203216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203216 about?
NCT00203216 is a clinical study titled "A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches". The study drug levetiracetam is FDA approved as an add-on medication in the treatment of partial onset seizures in adults with epilepsy. The trade name is Keppra®. This is an "open-label" trial, which means that all participating patients will receive active study drug. The Jefferson Headache Cente...
What is the current status of trial NCT00203216?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2002-09. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00203216?
The interventions under investigation include: levetiracetam (DRUG), Transcranial Magnetic Stimulation (PROCEDURE).
Who is sponsoring clinical trial NCT00203216?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.